Cargando…

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This study evaluated olaparib capsules in combination with liposomal doxorubicin (PLD) in patients with advanced solid tumours (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Conte, G, Sessa, C, von Moos, R, Viganò, L, Digena, T, Locatelli, A, Gallerani, E, Fasolo, A, Tessari, A, Cathomas, R, Gianni, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134498/ https://www.ncbi.nlm.nih.gov/pubmed/25025963 http://dx.doi.org/10.1038/bjc.2014.345

Ejemplares similares

A Mathematical Model for Thermosensitive Liposomal Delivery of Doxorubicin to Solid Tumour
por: Zhan, Wenbo, et al.
Publicado: (2013)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
por: Perez-Fidalgo, J.A., et al.
Publicado: (2021)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
por: Dean, E, et al.
Publicado: (2012)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
por: Khan, O A, et al.
Publicado: (2011)

Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
por: Rahman, A., et al.
Publicado: (1986)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
por: Pan, Xing Qing, et al.
Publicado: (2006)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy
por: Liu, Yanhong, et al.
Publicado: (2022)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

Mild hyperthermia accelerates doxorubicin clearance from tumour-extravasated temperature-sensitive liposomes
por: Al-Jamal, Wafa' T., et al.
Publicado: (2022)

Targeting doxorubicin encapsulated in stealth liposomes to solid tumors by non thermal diode laser
por: Ghannam, Magdy M., et al.
Publicado: (2016)

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
por: Perez-Fidalgo, J Alejandro, et al.
Publicado: (2019)

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
por: Wang-Gillam, Andrea, et al.
Publicado: (2014)

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
por: González-Manzano, R., et al.
Publicado: (1995)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
por: Gokhale, P. C., et al.
Publicado: (1996)

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
por: Fracasso, P M, et al.
Publicado: (2005)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
por: Franco, Yesenia L, et al.
Publicado: (2018)

Reply: (99m)Tc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Koukourakis, M I
Publicado: (2002)

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
por: Zhou, Xiaoju, et al.
Publicado: (2012)

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
por: Evans, T. R. Jeffry, et al.
Publicado: (2019)

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.
por: Mayer, L. D., et al.
Publicado: (1995)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome
por: Yadav, Nidhi, et al.
Publicado: (2015)

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes
por: Mehn, Dora, et al.
Publicado: (2017)

Pharmacokinetics of a liposomal formulation of doxorubicin in rats
por: Liu, Zongyu, et al.
Publicado: (2017)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
por: Aloss, Kenan, et al.
Publicado: (2023)

Recurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin
por: Read, William L., et al.
Publicado: (2017)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kdsbe1gfh8pgqjp41krbopcacg